1. New Paradigms in HR-Positive Advanced Breast Cancer

2. Topics for Discussion

3. First-Line PALOMA-2 Trial*: PFS Results

4. First-Line MONALEESA-2 Trial*: PFS

5. Subgroup Analysis of PFS: PALOMA-2

6. Deciding When to Use CDK4/6 Inhibitors in First-Line Setting

7. ESMO Magnitude of Clinical Benefit Scale

8. Increased QoL With Palbociclib Plus Fulvestrant In Previously Treated HR-Positive, HER2-Negative MBC

9. Second-Line PALOMA-3 Trial*: PFS

10. CDK4/6 Inhibitors: Tolerability

11. CDK4/6 Inhibitors: Incidence of Neutropenia

12. Recommended Palbociclib Dose Adjustments for Patients With Neutropenia

13. Novel Targets for Hormone Therapy in Breast Cancer

14. When Should CDK4/6 Inhibitors Be Used in Second-Line Setting?

15. Addition of Everolimus to Exemestane for Second-Line Treatment: BOLERO-2* PFS Analysis

16. PALOMA-3*: Postprogression Therapies

17. CDK4/6 Inhibitors: Biomarkers of Response and Resistance

18. CDK4/6 Inhibitors: Biomarkers of Response and Resistance (cont)

19. Availability of CDK4/6 Inhibitors for Treatment of HR-Positive, HER2-Negative MBC

20. Abbreviations

21. Abbreviations (cont)